NICOX
NicOx is a biopharmaceutical company, engages in the development and commercialization of nitric oxide (NO)-donating drugs primarily for inflammation and cardio-metabolic diseases. The company's primary products candidates include Naproxcinod, a Phase III product candidate for the treatment of osteoarthritis; and NCX 6560, a NO-donating compound for the treatment of cardiovascular diseases, which is in phase I clinical trials. Its product portfolio comprise PF-03187207 for the treatment of glauc... oma, TPI 1020 for the treatment of respiratory disorders, and NCX 1510 for allergic rhinitis, which are in Phase II clinical trials; and NO-donating antihypertensives, which is in phase I clinical trials for the treatment of hypertension. The company's product pipeline also include NCX 1047, which is in preclinical stage of development for treating a range of skin disorders, such as atopic dermatitis, psoriasis, and seborrheic dermatitis; and NO-donors for diabetic retinopathy, cardiometabolic, inflammation, and pain. It has research and co-development agreement with Orexo AB to identify and develop compounds for the treatment of airway diseases; license and development agreement with TOPIGEN Pharmaceuticals Inc. The company also has agreements with Grupo Ferrer Internacional SA for the research, development, and marketing of NO-donating anti-inflammatory drugs for the treatment of dermatological diseases; Pfizer Inc to identify nitric oxide-donating compounds for diabetic retinopathy; and Merck & Co., for the development of new antihypertensive drugs using NicOx' nitric oxide-donating technology. NicOx S.A. was founded in 1996 and is headquartered in Sophia Antipolis, France.
NICOX
Social Links:
Industry:
Biotechnology Health Care Medical Device
Founded:
1996-01-01
Address:
Valbonne, Provence-Alpes-Cote D'Azur, France
Country:
France
Website Url:
http://www.nicox.com
Total Employee:
51+
Status:
Active
Contact:
33 4 97 24 53 00
Email Addresses:
[email protected]
Total Funding:
149 M USD
Technology used in webpage:
Domain Not Resolving Person Schema Ubuntu Java EE Apple Whitelist 3 To 9 CcTLD Redirects Moodle
Similar Organizations
Almirall
Almirall is an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2014-09-16 | Doliage | Doliage acquired by NicOx | 5 M EUR |
| 2014-07-02 | Aciex Therapeutics | Aciex Therapeutics acquired by NicOx | 120 M USD |
| 2013-12-06 | EuPharmed | EuPharmed acquired by NicOx | N/A |
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-13 | Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Non-clinical Development |
Official Site Inspections
http://www.nicox.com Semrush global rank: 4.69 M Semrush visits lastest month: 2.05 K
- Host name: 45.92.108.78
- IP address: 45.92.108.78
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "NicOx"
About Us - Nicox
Nicox has a highly experienced leadership team. Their combined expertise, from leading pharmaceutical and biotech companies, covers research, clinical development, regulatory, …See details»
NicOx - Wikipedia
Nicox's lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating bimatoprost analog, for lowering intraocular pressure (IOP) in patients with glaucoma. NCX 470 is designed to release both bimatoprost, which is marketed under the brand name LUMIGAN, and nitric oxide following instillation into the eye. Bimatoprost is a prostaglandin analog, the most widely used class of drugs for IOP lowering in patients with open angle glauco…See details»
Nicox - LinkedIn
Nicox is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world. Our ...See details»
NicOx - Crunchbase Company Profile & Funding
Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.See details»
Nicox Group
Empowering Your Business SuccessSign up for our email list for updates, promotions, and more.See details»
NicOx Company Profile - Office Locations, Competitors, Revenue …
Jun 23, 2023 NicOx has 5 employees across 3 locations and €7.86 m in annual revenue in FY 2024. See insights on NicOx including office locations, competitors, revenue, financials, …See details»
Nicox - Overview, News & Similar companies | ZoomInfo.com
Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is …See details»
Nicox (LON:0RCQ) Company Profile & Description - Stock Analysis
Aug 4, 2025 Company profile for Nicox S.A. (LON:0RCQ) with a description, list of executives, contact details and other key facts.See details»
Nicox - Visible Science
Aug 8, 2025 Nicox develops innovative therapeutics to help maintain vision and improve ocular healthSee details»
NicOx Org Chart + Executive Team - The Official Board
The org chart of NicOx contains its 10 main executives including Gavin Spencer and John James.See details»
Nicox 2025 Company Profile: Stock Performance
Information on stock, financials, earnings, subsidiaries, investors, and executives for Nicox. Use the PitchBook Platform to explore the full profile.See details»
Nicox - LinkedIn
Nicox | 4,572 followers on LinkedIn. Maintain vision and improve ocular health | Nicox is an international ophthalmic R&D company, aiming to build a diversified portfolio of …See details»
What is Brief History of NicOx Company? – …
Jul 24, 2025 The NicOx company has achieved several significant milestones, particularly in advancing its nitric oxide-donating technology and its ophthalmic drugs. The company's …See details»
Nicox Overview | SignalHire Company Profile
Nicox Overview Nicox is a public company that has been in the industry for 28 years. The company currently specializes in the Pharmaceuticals area. The position of the Chairman & …See details»
News and events - Nicox
Jun 6, 2025 News and events Press releases August 21, 2025 Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients August 8, 2025 Nicox …See details»
NicOx - Profiles & Contacts - Crunchbase
Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.See details»
2022 ANNUAL REPORT - nicox.com
Nicox Ophthalmics Inc. was created on September 25, 2007 and is devoted to clinical development. The development team has an in-depth experience in chemistry, manufacturing …See details»
What are Mission Vision & Core Values of NicOx Company?
Jul 12, 2025 What Drives NicOx's Pursuit of Ophthalmic Innovation? Understanding a company's core principles is crucial for investors and stakeholders alike. NicOx, a leader in …See details»
Press Releases Archive - Nicox
Apr 30, 2025 Visible ScienceNews and eventsAll Press ReleasesSee details»
Nicox plans filings for glaucoma after phase 3 win
1 day ago Nicox is on track to file for approval of its NCX 470 therapy for eyesight-robbing disease glaucoma after it showed efficacy in a second pivotal trial. The positive data from the …See details»